Polycomb repressive complex 2 (PRC2) is involved in trimethylation of histone H3 lysine 27 (H3K27), chromatin condensation and transcriptional repression. The silencing function of PRC2 complex is mostly attributed to its intrinsic activity for methylating H3K27. Unlike in B-cell lymphomas, enhancer of zeste homolog 2 (EZH2) mutations in myeloid malignancies are inactivating/hypomorphic. When we assessed the mutational status in myeloid malignancies (N ¼ 469 cases examined), we found EZH2 and EED/SUZ12 mutations in 8% and 3.3% of cases, respectively. In addition to mutant cases, reduced EZH2 expression was also found in 78% cases with hemizygous deletion ( À 7/del7q cases involving EZH2 locus) and 41% of cases with diploid chromosome 7, most interestingly cases with spliceosomal mutations (U2AF1/SRSF2 mutations; 63% of cases). EZH2 mutations were characterized by decreased H3K27 trimethylation and increased chromatin relaxation at specific gene loci accompanied by higher transcriptional activity. One of the major downstream target is HOX gene family, involved in the regulation of stem cell self-renewal. HOXA9 was found to be overexpressed in cases with decreased EZH2 expression either by EZH2/spliceosomal mutations or because of À 7/del7q. In summary, our results suggest that loss of gene repression through a variety of mutations resulting in reduced H3K27 trimethylation may contribute to leukemogenesis.
INTRODUCTION
Chromosomal defects detected by conventional metaphase karyotyping are common in myelodysplastic syndromes (MDSs) and primary acute myeloid leukemia (AML). Of these, monosomy 7 or segmental deletions of 7q are frequently observed and are associated with a relatively poor prognosis. [1] [2] [3] Recent studies using single-nucleotide polymorphism array (SNP-A) technology identified the minimally affected region on chromosome 7 in an attempt to delineate potential candidate genes. 4, 5 One of these included a small region at 7q35-7q36.1 in a patient subsets described as a deletion interval, 6 in many cases is a copy-neutral loss of heterozygosity 7q (also referred to as somatic uniparental disomy or UPD). Through sequencing analysis of such patients, along with others, we have identified loss-of-function mutations in enhancer of zeste homolog 2 (EZH2) in MDS, overlap MDS/ myeloproliferative neoplasm (MPN) disorders, MPN and AML. [7] [8] [9] Reduced EZH2 enzymatic activity and thereby H3K27 methylation has been reported earlier. 10 Previously, EZH2 dysfunction has been widely implicated in numerous solid tumors, including prostate, 11 breast 12 and renal cell, 13 and more recently, follicular lymphoma, 14 in which EZH2 overexpression or gain-of-function mutations result in subsequent hypermethylation of histone H3 lysine 27 (H3K27). In contrast, to these cancers, identified EZH2 mutations in myeloid neoplasms comprised nonsense or frameshift mutations. Moreover, these mutations are found in homozygous configuration, [7] [8] [9] resulting in reduced enzymatic activity of the protein. Owing to the tight linkage of EZH2 to H3K27 and repressive chromatin patterns, 15 it has been hypothesized that myeloid cells with EZH2 mutations will have decreased repression of its downstream targets, contributing to leukemogenesis. 16 Supporting this hypothesis, other members of the polycomb repressive complex 2 (PRC2) such as SUZ12 and EED although analogous to EZH2 [8] [9] [10] but involved in gene repression via H3K27 trimethylation were also found to be inactivated in MDS/MPN and AML. 17, 18 Our earlier study suggested, in a small number of monosomy 7 cases haploinsufficiency of EZH2 represents another potential mechanism of PRC dysfunction in myeloid malignancies. 4 We have undertaken this study to systematically assess the impact of various lesions affecting the EZH2 gene expression on downstream molecular targets and its clinical consequences. We first analyzed a large cohort of patients with myeloid malignancies to perform clinical and prognostic analyses in EZH2 mutant cases versus those with wild-type (WT) EZH2 to define the impact of EZH2 mutations on clinical outcomes. In addition to mutations, we found that common deletions of the EZH2 locus lead to haploinsufficient expression in MDS and AML, while in cases with a diploid EZH2 locus, splicing dysfunction because of somatic spliceosome mutations is another mechanism for effective decreased expression of this gene. To better understand the molecular pathogenesis of mutated or haploinsufficient EZH2 expression, we investigated EZH2 histone methyltransferase activity and chromatin relaxation at target genes. To put EZH2 mutations into a clinical context, we explored survival associations, and integrated relationships of other genetic abnormalities affecting gene regulation identifying mutually exclusive and associated mutations.
MATERIALS AND METHODS Patients
Informed consent for sample collection was obtained according to protocols approved by institutional review boards of the participating institutions. Diagnoses were according to World Health Organization criteria and confirmed at each participating institution.
Metaphase cytogenetics and SNP-A karyotyping
Routine cytogenetic analysis was performed according to standard methods. For SNP-A analysis, DNA was extracted from patient marrow specimens and the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA) were used for SNP-A analysis as previously described. 15 Germline-encoded copy number variants and nonclonal areas of UPD were excluded from further analysis by utilizing a previously described bioanalytic algorithm based on lesions identified by SNP-A in an internal control series 19 and reported in the Database of Genomic Variants (http://projects.tcag.ca/variation/).
Mutational analysis using sanger sequencing
We analyzed a cohort of 469 patients, 161 of whom had MDS, 66 MPN, 114 MDS/MPN and 128 primary AML, to identify patients with EZH2 mutations. We also sequenced ASXL1 and TET2 in serial bone marrow samples in the chronic, accelerated and blast phase of a patient with atypical chronic myeloid leukemia. The somatic nature of the mutations was determined using immunoselected non-clonal CD3 þ cells. For EZH2, ASXL1, TET2, RUNX1, IDH1/2, NRAS, KRAS, DNMT3A, JAK2, UTX, CBL, MPL, FLT3, U2AF1 and SRSF2, direct bidirectional genomic sequencing was performed as previously described (Applied Biosystems, Foster City, CA, USA). 18, 20 Mutations were scored as pathogenic if they were not detected in nonclonal paired DNA samples, were not found in publically available SNP databases and/or they were not reported as SNPs in previous publications.
Quantitative (q)RT-PCR
Total RNA was extracted from CD34 þ cells and cell lines. Complementary DNA (cDNA) was synthesized from 500 ng total RNA using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Quantitative gene expression levels were detected using real-time PCR with the ABI PRISM 7500 Fast Sequence Detection System and FAM dye labeled TaqMan MGB probes (Applied Biosystems). TaqMan assay was performed according to the manufacturer's instructions. Primers and probes for all genes analyzed were purchased from Applied Biosystems gene expression assays products (EZH2: Hs01016789_m1; HOXA9: Hs00365956_m1; CDKN2A: Hs99999189_m1; MYC: Hs99999003_m1; PU.1: Hs00231368_m1; RUNX1: Hs01021970_m1; CEBPA: Hs00269972_s1; IRF4: Hs01056534_m1; RASSF1: Hs00945257_m1; GAPDH: Hs99999905_m1). The expression level of target genes was normalized to the GAPDH mRNA.
Direct chromatin PCR
Experiments were performed as previously published. 21 In brief, cell suspensions (1 Â 10 4 , untreated control or treated with trichostatin A; Sigma-Aldrich, St Louis, MO, USA) were placed in a PCR tube and placed at À 80 1C for at least 30 min followed by gradual thawing on ice. Fifty microliter of ice-cold chromatin extraction buffer (RPMI supplemented with 10% fetal bovine serum and 5 mM of EDTA) was added followed by intensive vortexing. Samples were placed in PCR cycler pre-chilled to 4 1C with lid preheated to 104 1C. 
Western blot analysis
Western blot was performed according to previously described methods. 8 Twenty-five microgram of protein extracts, together with molecular weight markers, were subjected to Nu-polyacrylamide gel electrophoresis followed by transfer and development with antibodies against trimethylated histone H3K27, whole histone H3 (Abcam, Cambridge, MA, USA) and EZH2 (Cell Signaling Technology, Danvers, MA, USA). Immunoblots were quantified by ImageJ, as previously described.
Immunofluorescence
Cells were cytospun onto slides and incubated overnight with the same anti-mouse antibodies as used for western blot analysis, followed by a 655 nm Quantum DotsTM-conjugated goat anti-mouse antibody (Invitrogen, Carlsbad, CA, USA). Finally, cells were stained with 3 mM 4,6-diamidino-2-phenylindole and examined with a Leica DMR light microscope (Leica Microsystems GmbH, Wetzlar, Germany).
RNA deep sequencing
Next-generation-based RNA deep sequencing was performed as previously reported. 19 Briefly, total RNA was extracted from bone marrow MNCs using the Nucleospin RNA II Kit (Macherey-Nagel, Bethlehem, PA, USA) with DNAase treatment. The integrity and purity of total RNA was assessed using Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). In all, 1-2 mg of cDNA was generated using Clontech SmartPCR cDNA kit (Clontech Laboratories, Inc., Mountain View, CA, USA) from 100 ng of total RNA. cDNA was fragmented using Covaris (Covaris, Inc., Woburn, MA, USA) and subjected to Illumina library preparation using NEBNext reagents (New England Biolabs, Ipswich, MA, USA). The quality and quantity and the size distribution of the Illumina libraries were determined using an Agilent Bioanalyzer 2100. The libraries were then submitted for Illumina HiSeq2000 sequencing according to the standard operation. Paired-end 90-bp reads were generated and subjected to data analysis using the platform provided by DNAnexus (DNAnexus, Inc, Mountain View, CA, USA; https:// dnanexus.com), which allowed visualization of reads derived from spliced mRNA and those that completely match the genome, including both sense and antisense.
Statistical analysis
For comparison of the expression levels between groups with and without EZH2 mutations, continuous variables were analyzed using the MannWhitney U-test. Overall survival was analyzed using Kaplan-Meier statistics and compared by log-rank test. All analyses were two-sided, with a P-value o0.05 defining significance.
Database search
For validating our results, expression array, SNP-A, RNA sequencing and whole-exome sequencing results were searched in databases; The Cancer Genome Atlas (TCGA) (http://cancergenome.nih.gov/) and Oncomine (https://www.oncomine.org/).
RESULTS
Clinical presentation in PRC2-associated gene mutation status and prognosis We first investigated the clinical significance of EZH2 mutations detected by sequencing of all coding exons (Supplementary Table S1 ). EZH2 mutations were frequently observed in MDS/MPN (8%) and MPN (3%) but rare in the groups of MDS (2.5%) and AML (2%; Figure 1a ). Overall, 19 mutant cases were identified. The mutations affected several parts of the EZH2 protein, including most commonly the SET (Su(var), Enhancer of zeste, Trithorax) domain, which transfer the methyl group from substrate to lysine residues. There were 10 missense, 5 frame shift and 4 nonsense mutations (Supplementary Figure S1A) .
For trimethylation of H3K27, EZH2 functions together with SUZ12 and EED in the PRC2 component. Using SNP-array, two AML cases were identified with microdeletions of 17q11.2 involving the SUZ12 locus (Supplementary Figure S1B) . In both of these cases, hemizygous SUZ12 missense mutations were found. In addition to these aberrations, patients also harbored a concomitant EED mutation in the WD40 repeat known to interact with EZH2 (Supplementary Figure S1C) . Overall, we found three SUZ12 and two EED mutations in four cases. Screening of other PRC2-associated genes, including JARID2 and RBBP4/7, revealed no additional mutations (data not shown). Overall, mutations involving PRC2 were present in 2.5% of MDS and 2.5% of AML samples.
When all patients were analyzed, the overall survival was significantly shorter in the cases with EZH2 mutation than in those with WT EZH2 (Figure 1b) . Similarly, in subgroup analyses, the prognosis of the cases with mutations was significantly worse in the MDS/MPN group in which the mutations were most common ( Figure 1b ) and in patients 460 years old (Supplementary Figure S2) . Similarly significant effects on survival were also observed when all patients with PRC2 mutations (EZH2/SUZ12/ EED) were studied (data not shown).
Loss-of-function of histone H3K27 trimethyltransferase in EZH2 mutant cases The effect of mutations on the trimethylation function of EZH2 has been investigated in index cases with MDS/MPN and EZH2 homozygous mutation (Supplementary Figure S3) . Western blot analysis and immunostaining revealed decreased trimethylation of H3K27 compared with healthy controls in both the chronic and leukemic phase (Figures 1c and d) . A similar effect on H3K27 were detected by western blot using bone marrow mononuclear cells from a healthy donor, a case with EZH2 mutation in chronic and leukemic phase respectively and three cases with WT. (e) Fold expression of EZH2 mRNA by real-time PCR was performed using SKM1 and three control cell lines without mutation (KG1, K562 and NKM1). (f, g) EZH2 and H3K27me3 were detected by western blot using an EZH2 mutant cell line (SKM-1) and two WT/without mutation cell lines (KG1 and K562). Protein expression was quantified by ImageJ for better insight.
methylation was observed in EZH2 Y641C mutant (cosmic database) SKM-1 cells derived from a patient with MDSs compared with a selection of cell lines with WT EZH2 (Figure 1g ). EZH2 protein and gene expression were observed both in SKM-1 and WT cell lines (Figures 1e and f) .
Loss of histone H3K27 methyltransferase function of EZH2 in spliceosome-associated gene mutation As per our analysis, cases with WT EZH2 locus that harbored spliceosomal mutations were often related to similar phenotype with low level of EZH2 expression. Hence, we hypothesized that spliceosomal dysfunction caused by somatic spliceosomal mutations may affect processing of EZH2 pre-mRNA and ultimately lead to decreased expression of EZH2. Whole RNA-sequencing based quantification of gene expression showed that the relative amount of pre-mRNA of EZH2 was decreased in cases with U2AF1 (n ¼ 9) and SRSF2 (n ¼ 4) mutations, compared with cases with WT (Figure 2a) , which results in more than twofold difference in EZH2 expression (Figure 2b) . Further analyses at each exonintron boundary of RNA-sequencing showed that more unspliced EZH2 pre-mRNA than spliced transcript was observed in AML cases with U2AF1 mutation in intron 10 and 11 ( Figure 2c) . Similarly, EZH2 expression levels were also found to be reduced in the AML cases with U2AF1 (n ¼ 9) and SRSF2 (n ¼ 2) mutations, at levels similar to those seen in cases with del7q (Supplementary Figure  S4B) . To confirm our theory that splicing defects lead to loss of EZH2 function, we checked the levels of EZH2 protein and trimethylated H3K27. Immunofluorescence showed low EZH2 followed by lower trimethylation of H3K27 in cases with spliceosomal mutations than was seen in WT (Figures 3a-d) .
Hence, showing loss of H3K27 marks in lower EZH2 expressing patients (either spliceosomal mutants or -7/del7q).
Decreased expression of EZH2 Decreased H3K27 trimethylation function by PRC2 may be due to decreased expression of its components; functionally such a situation may have similar consequences as inactivating mutations. To clarify the contribution of altered EZH2 expression to myeloid malignancies, we compared EZH2 expression between healthy controls and myeloid malignancies using expression array analyses (Oncomine; https://www.oncomine.org/). EZH2 expression was decreased (95% confidence interval) in 3.4% of MDS and 14% of AML samples compared with healthy controls (Supplementary Figure S4A) . Haploinsufficient expression was found in 78% of patients with deletion of EZH2 locus and was less frequent in 75 (41%) patients without deletion of the EZH2 locus (as defined by 95% confidence interval of cases without del7q or spliceosomal mutations) (Supplementary Figure S4B) . In particular, 63% of patients with spliceosomal mutations (U2AF1/SRSF2 mutations cases) were associated with decrease EZH2 expression. The results from expression array analyses were further confirmed by real-time PCR using CD34 þ cells from AML cases (Supplementary Figure S4C) . Such a confirmation was also carried out for a significant proportion of cases with a diploid EZH2 locus in our sample cohort. Thus, cumulatively EZH2 dysfunction may be expected in 37% because of its mutation, 11% of cases because of misplicing in U2AF1/SRSF2 mutations and in 24% of cases because of haploinsufficient expression.
Chromatin relaxation and induced transcription in EZH2 mutation
We investigated the effects of EZH2 loss-of-function mutations on the expression profile of genes known to be epigenetically regulated by EZH2.
22,23
Real-time PCR analyses revealed upregulation of HOXA9, PU.1, CDKN2A, IRF4, RASSF1 and CEBPA mRNA level in SKM-1 compared with EZH2 WT cell lines (Figure 4) . To explain the association between decreased trimethylation levels of histone H3K27 and gene expression, we studied sitespecific chromatin configuration with our recently published novel method, 21 which allows assessment of transcriptional activity and accessibility of specific gene regions. Here, we studied the effect of EZH2 mutations on the chromatin accessibility by direct chromatin PCR of CDKN2A, PU.1 and MYC gene regions, using PCR-based analysis of cellular chromatin state. Direct chromatin PCR is based on the chromatin-stabilizing effects of hypotonic PCR buffer, which prevents global cellular chromatin accessibility during thermal cycling while active chromatin with weaker DNA-protein interactions becomes accessible for primers to be amplified. 21 The EZH2 mutant SKM-1 cell line displayed a more open chromatin profile for CDKN2A and PU.1 gene regions than the EZH2 WT cell lines KG-1 and K562. Although MYC, a gene not under epigenetic control by EZH2, was equally relaxed in K562 cells. Treatment of cells with the histone class I and II deacetylase inhibitor trichostatin A before direct chromatin PCR, increased primer access for select sites in each cell line, confirming the epigenetic read-out of the technique and suggesting that epigenetic mechanisms other than histone class I and II deacetylases mediate chromatin condensation (Supplementary Figure S5) . Furthermore, we extrapolated the result from cell line and analyzed the expression profile of HOXA9 as one of the PRC2 targets in patient cohort. HOXA9 was found to be overexpressed in cases with del7q and spliceosomal mutations compared with cases without these defects (Supplementary Figure S4D) . This corroborates our data on higher HOXA9 expression in lower EZH2 expressing cells. Similar pattern was also observed for HOXA10 expression (data not shown). EZH2 low expression and lower H3K27 trimethylation profiles were further confirmed in EZH2 non-mutated patients but with À 7/del7q and spiceosomal defects. The results confirmed lower EZH2 expression associated with spliceosomal mutations and À 7/del7q, which further results in lower H3K27 trimethylation.
Additional molecular events concomitant with EZH2 mutations
In index cases of secondary AML evolving from MDS/MPN, in addition to EZH2, we detected three other somatic mutations affecting other genes, including nonsense ASXL1 and frame shift TET2 mutations (Supplementary Figure S3) . We also found these three mutations in serial analyses, including at presentation and before transformation into AML, but not in germ line DNA from CD3 þ cells. In an extended cohort of EZH2 mutant cases, concomitant ASXL1 mutations were present in 33% and TET2 in 67% of cases ( Figure 5 ). To gain a better understanding of the biology underlying EZH2 mutations, we also sequenced 11 other genes (RUNX1, IDH1/2, NRAS, KRAS, DNMT3A, JAK2, UTX, CBL, MPL and FLT3-ITD) frequently mutated in myeloid malignancies and performed SNP array-based karyotyping to correlate the presence of EZH2 mutations with other molecular lesions. Overall, TET2, RUNX1 and ASXL1 were the most frequently mutated in cases with EZH2 mutations, whereas EZH2 and UTX mutations (an H3K27 demethylase) were mutually exclusive (Figure 5a ). Circos analysis (http://mkweb.bcgsc.ca/tableviewer/) of mutual relationship between EZH2 and other mutated genes illustrates the association of EZH2 with accessory mutations (Figure 5b ). The most frequent chromosomal aberrations concomitant to EZH2 mutations included, in addition to UPD7q, trisomy 8 (10/17 cases; Figure 5c ).
DISCUSSION
Targeted and whole-genome sequencing in MDS and related disorders led to the discovery of various gene mutations involved in the epigenetic regulation, providing a functional link between mutational events and putative epigenetic instability. The EZH2 gene, an H3K27 trimethylase is affected by recurrent mutations in MDS and related disorders. [7] [8] [9] We have investigated the pathogenic significance of EZH2 in myeloid malignancies. We demonstrate here that various mechanisms can lead to decreased trimethylation activity of EZH2, which includes loss-of-function mutations and deficient gene expression. Deficient expression can be due to haploinsufficiency in cases with -7/del7q or because of other mechanisms in cases with diploid EZH2 locus. Our study shows that one mechanism may be splicing failure of EZH2 premRNA in cases associated with mutations in U2AF1. Spliceosome genes, in particular U2AF1, SF3B1 and SRSF2 are frequently affected by mutations in MDS, primary and secondary AML and MDS/MPN. 24, 25 Thus, the prevalence of PRC2 dysfunction in myeloid malignancies is greater than the frequency of EZH2 mutations.
In addition, this study documented hemizygous SUZ12 mutations and EED mutations affecting the WD40 domain, which is involved in trimethylation of H3K27. Thus, H3K27 trimethylation can be affected by mutations of a variety of genes through various mechanisms resulting in a convergent pathogenic mechanism. Clinically, the poor prognosis associated with EZH2 mutations suggests that EED and SUZ12 may convey similarly poor risk. Based on frequencies of À 7/del7q and spliceosomal mutations in myeloid malignancies, haploinsufficient expression of EZH2 is likely more common than somatic mutations of EZH2; together, decreased trimethylation of H3K27 may be a much more ubiquitous pathway than could be extrapolated from mutational frequencies of EZH2.
Clinically, EZH2 mutations are observed in patients within all risk groups, frequently detected in myeloproliferative phenotypes and most frequently associated with ASXL1. The presence (vs the absence) of EZH2 mutations was strongly associated with decreased overall survival, in agreement with previous reports. 7, [26] [27] [28] Mutations in the WD40 domain of EED imply that PRC2 is likely impaired because of mutations in these genes and, also is closely associated with SUZ12. 17 Consequently, we would expect a similarly serious prognosis associated with these gene mutations, but because of the low numbers of patients with these mutations, their clinical impact cannot be rigorously tested.
Unfavorable prognosis of EZH2 mutant cases parallels those of À 7/del7q, likely due to the haploinsufficient expression of EZH2. A similar poor prognosis may be also associated with decreased EZH2 expression of WT EZH2. We have demonstrated here that decreased EZH2 expression may be due to splicing failure caused by spliceosomal mutations. We have recently demonstrated the negative impact of U2AF1 mutations on outcome parameters. 24 Such prognostic association between EZH2 and U2AF1 might be the reason why U2AF1 and EZH2 mutations are mutually exclusive. In such settings, gene transcription induced by chromatin relaxation follows reduced trimethylation of histone H3K27. In addition to mutations, haploinsufficiency and splicing abnormality are responsible for loss of EZH2 function.
In myeloid malignancies, somatic mutations in various genes involved in epigenetic regulation have been recently described, including EZH2, ASXL1, TET2 and UTX. [29] [30] [31] [32] Considering the functional implications, our study focused on the potential effects of mutational combination. ASXL1 is involved in demethylation of histone H3K4, in which trimethylation induces chromatin relaxation or transcriptionally active state.
14 Loss of ASXL1 function theoretically leads to increased H3K4 methylation, which might be followed by an increased gene transcription. Clinically, the presence (vs the absence) of mutations of ASXL1 carried a worse prognostic risk in various myeloid neoplasms. 26, 33, 34 That ASXL1 was the second most commonly mutated gene identified in the cases with EZH2 mutations suggests that EZH2 and ASXL1 might be genetically and clinically associated with each other through epigenetic regulation. Similarly, the absence of an association between mutations of UTX, which functions as a demethylase of histone H3K27, and EZH2 mutations, implies mutually opposite effects to the mutations. Mutations of TET2, which are most frequently observed in EZH2 mutants, were associated with a decrease in the level of 5hmc affecting DNA methylation, thereby overall chromatin configuration.
Trimethylation of histone H3K27 is a repressive mark leading to chromatin condensation. 35, 36 If EZH2 mutations reduce methyltransferase function, as previously reported, 7, 8 gene transcriptions can theoretically be induced because of opened chromatin and better genomic accessibility. Our data on gene expression in mutated EZH2 and non-mutated cells associates the mutation of EZH2 gene with characteristic functional consequences on gene expression. Upregulation of developmental oncogene HOXA9 was observed in an EZH2 mutated cell line compared with non-mutated, which corroborates the pathway linkage of EZH2 and HOXA9 reported earlier. 37, 38 Configuration of more transcriptionally active states in EZH2 mutants was also confirmed by our novel chromatin condensation assay, in which chromatin was more accessible to epigenetic modifier in EZH2 mutant than non-mutated counterpart when amplified with primers for specific gene of interest. Our results illustrate a less condensed or more transcriptionally active chromatin state in EZH2 mutated cells compared with non-mutated, which confirms epigenetic dysregulation and transcriptional activation by loss-of-function EZH2 mutations found in myeloid neoplasias.
Another mechanism of loss of EZH2 function is defective splicing because of spliceosome mutations. Intron retention might result in pre-mRNA nonsense decay. Interestingly, such unspliced introns and reduced expression of EZH2 were observed in U2AF1 and SRSF2 mutant compared with non-mutated cases. Moreover, along with others, we recently reported 24, 39, 40 that U2AF1 and SRSF2 mutations are very frequently detected in the more proliferative subgroups of myeloid malignancies with worse prognosis, whereas SF3B1 mutations carry a more favorable prognostis. 24, 39, 40 We conclude that spliceosomal mutations might be one of the mechanisms, which are not associated with LOH7, but rather lead to loss of EZH2 function, similar to mutations or haploinsufficiency.
Polycomb group of proteins are known as a multifaceted regulator of normal and cancer stem cells and are associated in fine regulation of stem cell self-renewal and fate decision. 41, 42 HOXA9 was found to be activated in EZH2 mutant cell line (SKM-1) and further analyses in patient cohort illustrates that HOXA9 and HOXA10 are derepressed in EZH2-deficient or lower expressing cells. Both genes are validated oncogenes in the development of myeloid leukemia. Overexpression of HOXA9 alone or in combination with other genes can efficiently induce myeloid leukemia development in bone marrow transduction and transplantation studies in mice. 43 Interestingly, HOXA9 overexpression has been reported to trigger immortalization of myeloid progenitors in vitro, implicating their role in self-renewal of myeloid progenitors. 44 In accordance with these reports, our results strongly suggest that activation of HOXA9 and HOXA10 with repression of EZH2 could induce leukemia transformation by promoting the self-renewal of leukemic stem cells. Overall, our results implicate a novel mechanism by which multiple events can be responsible for EZH2 repression and further contribute to leukemia transformation via activating HOX oncogenes.
The results from this study illustrate that, approaches aimed at restoring H3K27 trimethylation and thereby chromatin repression may yield therapeutic benefit in myeloid neoplasias with a variety of upstream mutations. One such approach might be with selective inhibitors of H3K27 demethylases; a recent study documented that the catalytic site of jumonji H3K27 demethylase can be targeted with small molecules. 45 Alternatively, targeting de-repressed genes like HOXA9 may not only be of benefit to leukemias characterized by MLL mutations where the role of HOXA9 for leukemogenesis was first described but also in leukemias with a variety of mutations affecting H3K27 trimethylation.
In summary, loss of EZH2 function in myeloid disorders can occur through multiple mechanisms, including homozygous mutations with UPD7q, haploinsufficiency with À 7/del7q and through phenocopy of less EZH2 expression by spliceosome mutations. Such EZH2 abnormalities may contribute to leukemogenesis ( Figure 6 ) through inappropriate release of genes like HOXA9 from repression by H3K27 trimethylation.
